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Bovine herpesvirus 1 (BHV-1) interferes with peptide translocation by the transporter associated with
antigen processing (TAP). Recently, the UL49.5 gene product of BHV-1 was identified as the protein respon-
sible for the observed inhibition of TAP. In BHV-1-infected cells and virions, the UL49.5 protein forms a
complex with glycoprotein M (gM). Hence, it was investigated whether UL49.5 can combine the interactions
with gM and the TAP complex. In cell lines constitutively expressing both UL49.5 and gM, UL49.5 appears to
be required for functional processing of gM. Immunofluorescence-confocal laser scanning microscopy dem-
onstrated that both proteins are interdependent for their redistribution from the endoplasmic reticulum to the
trans-Golgi network. Remarkably, expression of cloned gM results in the abrogation of the UL49.5-mediated
inhibition of TAP and prevents the degradation of the transporter. However, in BHV-1-infected cells, differ-
ences in UL49.5 and gM expression kinetics were seen to create a window of opportunity at the early stages of
infection, during which time the UL49.5 protein can act on TAP without gM interference. Moreover, in later
periods, non-gM-associated UL49.5 can be detected in addition to the UL49.5/gM complex. Thus, it has been
deduced that different functions of UL49.5, editing of gM processing and inhibition of TAP, can be combined
during BHV-1 infection.
Bovine herpesvirus 1 (BHV-1) belongs to the subfamily
Alphaherpesvirinae and the genus Varicellovirus. BHV-1 infec-
tions affect the respiratory tract, the eyes, and the reproductive
tract of cattle (9). BHV-1 downregulates the cell surface ex-
pression of major histocompatibility complex (MHC) class I
molecules to evade recognition by host cytotoxic T cells (10,
19). Recently, it was demonstrated that the product of the
BHV-1 UL49.5 gene blocks the transporter associated with
antigen processing (TAP) (18). The TAP complex consists of
two subunits, TAP1 and TAP2, and is combined with MHC
class I molecules and several other accessory molecules in the
MHC class I peptide-loading complex (5, 37). TAP translo-
cates antigenic peptides from the cytosol into the endoplasmic
reticulum, where they are loaded onto newly synthesized MHC
class I molecules. TAP thus mediates an essential function in
the MHC class I antigen presentation pathway (5, 37). Cells
expressing UL49.5 show a strongly reduced MHC class I sur-
face expression and demonstrate a severely impaired capacity
to activate cytotoxic T cells (18).
UL49.5 expression yields a type 1 transmembrane protein
with a predicted size of 96 amino acids and an apparent mo-
lecular mass of 9 kDa. The protein can be detected at the cell
surface and in the virion membrane (26). The UL49.5 polypep-
tide has a cleavable N-terminal signal peptide of 22 amino
acids (18), a predicted extracellular domain of 32 amino acids,
a transmembrane region of 25 amino acids, and a cytoplasmic
tail of 17 amino acids (25). The extracellular domain of UL49.5
contains a cysteine residue that is highly conserved among the
UL49.5 homologs encoded by other members of the herpesvi-
rus family. The UL49.5 protein can be coprecipitated with the
TAP complex and may interact with the TAP1 and/or TAP2
proteins directly or through one of the other proteins in the
MHC class I peptide-loading complex. The interaction of the
UL49.5 protein with the TAP complex blocks conformational
rearrangements in TAP required for peptide translocation into
the endoplasmic reticulum (ER). In addition, UL49.5 induces
degradation of the transporter and the UL49.5 protein itself
(18). A truncated form of the UL49.5 protein lacking the
cytoplasmic tail can still block the translocation of peptides,
but it fails to trigger degradation of the TAP complex (18).
The BHV-1 UL49.5 protein is a homolog of the highly con-
served glycoprotein N (gN) found in all herpesviruses studied
to date (6). Like its homologs in several other species, the
BHV-1 UL49.5 is not glycosylated (26). All gN homologs
investigated so far form a complex with the transmembrane
(glyco)protein M (gM) (8, 15, 21, 23, 30, 34, 39). The gN/gM
complex is implicated in such processes as maturation of
virions and control of membrane fusion (31, 32, 40). The
immune evasion properties of UL49.5 have been found in
several varicelloviruses, including pseudorabies virus and
equine herpesvirus 1 in addition to BHV-1 (18).
The BHV-1 gM protein is encoded by the UL10 gene and is
a type IIIa protein with a predicted size of 438 amino acids
(National Center for Biotechnology Information database, ac-
cession number gi:9629818). It contains a proline-cysteine pair
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at amino acid positions 44 and 45 from the N terminus, in the
first extracellular domain. This proline-cysteine pair is highly
conserved within the gM homologs encoded by other members
of the herpesvirus family. The BHV-1 gM-coding region has
one predicted N-glycosylation site, located at the putative ex-
tracellular domain at amino acid residue 56 (39). The extra-
cellular domain is followed by seven predicted hydrophobic
domains separated by hydrophilic regions of 10 to 30 amino
acids, consistent with a multiple-transmembrane domain (pre-
dicted using the TMHMM2 program). A putative cytoplasmic
tail of 100 amino acids follows the putative transmembrane
domain. The predominant gM protein found in BHV-1-in-
fected cells and in BHV-1 virions has an apparent molecular
mass of about 43 kDa (39). BHV-1 gM is a late protein that can
first be detected 9 h postinfection (39). Both glycosylated and
nonglycosylated gM can be coprecipitated with the UL49.5
protein from infected cells, and there is evidence that UL49.5
and gM are covalently linked by a disulfide bond (39). The
UL49.5 protein can also form a disulfide-linked 15-kDa ho-
modimer (26), but it seems to bind gM as a monomer (39).
How many UL49.5 molecules react with the TAP complex is
still unknown.
To study whether the complex formation between BHV-1
gM and UL49.5 has an effect on the inhibition of the TAP
transporter, two approaches were followed. First, the assembly
of UL49.5/gM complexes and TAP inhibition were studied
using retrovirus-transduced cell lines constitutively expressing
wild-type UL49.5 or UL49.5 mutants, together with gM. The
second approach involved investigation of the UL49.5/gM
complex formation and its effect on TAP inhibition in BHV-
1-infected cells. It was found that UL49.5/gM association can
indeed interfere with the inhibition of TAP. In BHV-1-in-
fected cells, however, there appears to be sufficient non-gM-
bound UL49.5 protein to surpass this interference.
MATERIALS AND METHODS
Cells and viruses. Madin-Darby bovine kidney (MDBK) cells (American Type
Culture Collection) and the human melanoma Mel JuSo cells (MJS; obtained
from J. Neefjes, The Netherlands Cancer Institute, Amsterdam) were grown in
RPMI 1640 medium, supplemented with 10% fetal bovine serum, at 37°C in a
5% CO2 humidified atmosphere. BHV-1 (Dutch field strain Lam) and its virion
host shutoff (vhs) deletion mutant (19) were propagated and titrated on MDBK
cells. BHV-1 infections were performed on MDBK or MJS cells as previously
described (20).
Retroviral transduction. The construction of MJS cell lines, expressing wild-
type BHV-1 UL49.5 or its mutated version lacking the cytoplasmic tail (UL49.5
tail), was described elsewhere (18). MJS cells expressing the UL49.5 protein
that misses both the cytoplasmic tail and the transmembrane region (UL49.5
tail TM) and MJS cells expressing BHV-1 gM or gM in combination with
wild-type or truncated UL49.5 were made as follows. First, the coding region for
UL49.5 tail TM was amplified from the plasmid pCDNA3-IRES-NLS-GFP-
UL49.5 (18) using the following primers: forward, 5-CAGAATTCACCATGC
CGCGGTCG-3; reverse, 5-AACGAATTCTCACTGCGGTGGCTCCG-3.
The obtained PCR product was inserted into the pLZRS-IRES-GFP retrovirus
vector upstream of the internal ribosome entry site (IRES). The BHV-1 UL10
sequence encoding gM was amplified from purified BHV-1 Lam DNA using the
following primers: forward, 5-CACGAATTCATAGCA-3; reverse, 5-GGGG
ATCCCGTCATGGCGGG-3. The PCR product was inserted into the pLZRS
retrovirus vector upstream of the IRES and the truncated nerve growth factor
receptor-encoding sequence (pLZRS-IRES-NGFR). PCRs were performed
under standard conditions using Pfu DNA polymerase (Invitrogen). A single-
amino-acid difference, Gly243Ala24 (strain Lam), in gM was observed in com-
parison with the GenBank sequence (accession number gi:9629818). Recombi-
nant retroviruses were obtained in the Phoenix amphotropic packaging system as
described previously (http://www.stanford.edu/group/nolan/retroviral_systems
/retsys.html). MJS or MJS-UL49.5 cells were transduced with recombinant ret-
roviruses to generate the following cell lines: MJS gM, MJS UL49.5/gM, MJS
UL49.5 tail TM, MJS UL49.5 tail TM/gM, MJS UL49.5 tail, and MJS
UL49.5 tail/gM. The GFP-positive and NGFR-positive cells were sorted using
a FACSVantage cell sorter (Becton Dickinson).
Antibodies. The antibodies used in this study included two BHV-1 UL49.5
monospecific polyclonal rabbit sera raised against two synthetic peptides. The
N-terminal peptide H11 (RDPLLDAMRREGAMDFWSAGCYARGVPLS
EKK) was conjugated to glutathione S-transferase (GST) purified from the
pGEX system according to the manufacturer’s instructions (Amersham). The
conjugation was performed with 0.05% glutaraldehyde (Sigma-Aldrich) accord-
ing to the method described by Hancock et al. (11). The S-acetylmercaptoacetic
acid (SAMA) group was coupled to the C-terminal peptide H19 (RLMGASGP
NKKESRGRG) as described previously (14). The SAMA peptide was subse-
quently conjugated to bromoacetylated GST (14). Rabbits were injected intra-
dermally with the peptide-GST conjugates emulsified in Freund’s complete
adjuvant. At 3-week intervals, the rabbits received four additional subcutaneous
immunizations with the conjugates emulsified in Freund’s incomplete adjuvant.
For the production of the polyclonal rabbit serum raised against the 63 C-
terminal amino acids of BHV-1 gM, the recombinant gMC-63 construct was used
(a kind gift of G. J. Letchworth, Agricultural Research Service, USDA, Laramie,
WY) (39). Rabbits were immunized according to the protocol described above.
A BHV-1 vhs-specific polyclonal rabbit serum was raised against a His-tagged
UL41 protein produced in baculovirus and purified on Ni-tris-carboxymethy7l
ethylene diamine columns (A&A Biotechnology, Poland). gM- or UL49.5-spe-
cific mouse polyclonal sera used in immunoblotting detection of gM/UL49.5 in
immunoprecipitates were a kind gift of G. J. Letchworth (39). Anti-TAP1 mono-
clonal antibody (MAb) 143.5 was kindly provided by R. Tampe´ (Institute of
Biochemistry, The Johann Wolfgang Goethe University, Frankfurt, Germany),
anti-TAP2 MAb 435.3 was a kind gift from P. van Endert (INSERM U25,
Institute Necker, Paris, France), and anti-human MHC class I complex MAb
W6/32 was kindly provided by H. Ploegh (Whitehead Institute/MIT, Cambridge,
Mass.). Anti-BHV-1 gB MAb14 and anti-BHV-1 gC MAb71 were obtained from
the Animal Sciences Group, Lelystad, The Netherlands. A monoclonal antibody
directed against human beta-actin was purchased from Sigma-Aldrich.
Flow cytometry. Cell surface expression of specific molecules was determined
by indirect immunofluorescence using primary antibodies as indicated and, as a
second step, goat anti-mouse immunoglobulin (Ig)-phycoerythrin (Jackson Lab-
oratories) (20). To determine the viability of the cells, a 1 l of 1 mg ml1 of
7-aminoactinomycin D (7-AAD; Calbiochem) was added to the cells 20 min prior
to the analysis. Cells were analyzed using a FACSCalibur flow cytometer (Becton
Dickinson) and CellQuest software.
Metabolic labeling, pulse-chase analysis, immunoprecipitations, and immu-
noblotting. Mock-infected or BHV-1-infected cells were metabolically labeled with
[35S]methionine/cysteine mix (200 Ci ml1; 35S Redivue Promix; Amersham) for
35 min and lysed in a buffer containing 1% (wt/vol) digitonin (Calbiochem), 50 mM
Tris-HCl, pH 7.5, 5 mM MgCl2, 150 mM NaCl, 1 mM leupeptin, 1 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride (AEBSF), and 20 M Cbz-L3 (Peptides Inter-
national, Inc.). After removal of cell nuclei and debris by centrifugation, aliquots of
the cell lysates were precipitated with trichloroacetic acid, and radioactivity was
measured. Samples with equal amounts of incorporated radioactivity were subjected
to immunoprecipitation with anti-gM and anti-UL49.5 antibodies. Precipitates were
treated at 56°C with sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) sample buffer (2% SDS, 50 mM Tris pH 8.0, 10% glycerol, 0.05%
bromophenol blue) under nonreducing or reducing conditions, i.e., in the absence or
presence of 5% -mercaptoethanol, respectively. The samples were separated on
13% SDS-polyacrylamide gels. The gels were exposed to phosphor imaging screens,
which were scanned using a Personal Molecular Imager FX (Bio-Rad) and analyzed
using Quantity One software (Bio-Rad).
Where indicated, the cells were infected with BHV-1 in the presence of
phosphonoacetic acid (PAA; MP Biomedicals) at a concentration of 300 g ml1
to prevent late viral gene expression.
For immunoblotting analysis, the cells were lysed in NP-40 lysis mix containing
50 mM Tris-HCl, pH 7.4, 5 mM MgCl2, and 0.5% NP-40, supplemented with
1 mM AEBSF, 1 mM leupeptin, and 20 M Cbz-L3. Lysates were incubated
at 56°C in a reducing SDS-PAGE sample buffer, separated by SDS-PAGE,
and blotted onto polyvinylidene difluoride membranes. The membranes were
blocked overnight with 5% (wt/vol) skim milk in TBST (10 mM Tris-HCl, pH 8.0,
150 mM NaCl, 0.1% Tween 20), incubated for 60 min with anti-gM or anti-H11
serum diluted 1:500 in 3% milk-TBST, and, after extensive washing with TBST,
reacted with peroxidase-labeled anti-rabbit antibody (1:2,000; DAKO). MAbs
directed against TAP1, TAP2, or actin were used as previously described (18).
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Peroxidase-labeled anti-mouse antibody (1:1,000; DAKO) was used for the de-
tection of the immune complexes using ECL Plus (Amersham).
gM was depleted from digitonin lysates of BHV-1-infected cells by three
rounds of immunoprecipitation with anti-gM serum. The immune complexes
were isolated with protein A/protein G-Sepharose (Amersham), and the lysates
were clarified with Sepharose beads before the next round of immunoprecipita-
tion. The gM-depleted lysate was used to immunoprecipitate UL49.5 as de-
scribed above.
Analysis of N-linked glycosylation. Equivalent amounts of NP-40 cell lysates
were incubated with endo--N-acetylglucosaminidase H (EndoH; New England
Biolabs) or peptide:N-glycosidase F (PNGase F; Roche) according to the man-
ufacturers’ conditions. The reactions were terminated by the addition of SDS-
PAGE sample buffer. The samples were separated by SDS-PAGE and analyzed
by immunoblotting.
Immunofluorescence. MJS cells were grown on microcover glass, fixed with
4% paraformaldehyde in phosphate-buffered saline (PBS), and permeabilized
with 0.2% Triton X-100 in PBS for 5 min. UL49.5 was detected with H11
anti-UL49.5 serum (1:8,000 dilution). gM was stained with anti-gM serum (1:
5,000), trans-Golgi membranes were stained with anti-Golgin 97 MAbs (Molec-
ular Probes; 1:200), and concanavalin A (ConA)-Alexa 488 conjugate (Molecular
Probes; 1:10,000) was used as the ER and cis-Golgi marker. All antibody dilu-
tions were prepared in PBS containing 1% bovine serum albumin (Sigma-
Aldrich). Following three washes with PBS, the cells were incubated with sec-
ondary antibodies (1:3,000; Molecular Probes). gM and UL49.5 were visualized
with Alexa 594-conjugated goat anti-rabbit IgG. Golgin 97 was visualized with
Alexa 633-conjugated goat anti-mouse IgG. The blue signal was electronically
converted into green after the analysis of the images using a Nikon ECLIPSE
TE300 confocal laser scanning microscope.
Peptide transport assay. The fluorescein-labeled peptide transport assay was
performed as previously described (18). Briefly, MJS cells were permeabilized
with 2 IU ml1 of Streptolysin O (Murex Diagnostics Ltd.) at 37°C for 15 min.
The cells (2  106 cells/sample) were subsequently incubated with 20 l (30
pmol l1) of the fluorescein-conjugated synthetic peptide CVNKTERAY in
the presence or absence of 10 l of 100 mM ATP at 37°C for 10 min. Peptide
translocation was terminated by adding 1 ml of ice-cold lysis buffer containing
1% Triton X-100. After 20 min of lysis, cell debris was removed by centrifugation
and supernatants were collected and incubated at 4°C for 1 h with 100 l of
concanavalin A (ConA)-Sepharose (Amersham) to isolate the glycosylated pep-
tides. After extensive washing of the beads, the peptides were eluted with elution
buffer (500 mM mannopyranoside, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0) by
rigorous shaking for 1 h at 25°C. Eluted peptides were further separated from
ConA by centrifugation at 12,000  g. The fluorescence intensity was measured
using a fluorescence plate reader (CytoFluor, PerSeptive Biosystems) with exci-
tation and emission wavelengths of 485 nm and 530 nm, respectively.
RESULTS
BHV-1 UL49.5 forms a complex with gM outside the context
of viral infection and is required for gM maturation. To study
the influence of the UL49.5/gM complex formation on the
inhibition of the TAP transporter, MJS cells expressing UL49.5
and capable of showing the TAP inhibition (18) were trans-
duced with a recombinant retrovirus expressing gM. Two ma-
jor forms of gM, with molecular masses of 36 and 45 kDa,
respectively, were detected in the MJS UL49.5/gM cells (Fig. 1A,
lane 6). These products resemble the forms of gM found in
BHV-1-infected cells (Fig. 1A, lane 3), albeit with different
ratios between the 36-kDa and 45-kDa species. The difference
in mobility of the higher molecular mass forms of gM is due to
an artifact in the gel. Treatment of the samples with PNGase F,
which removes all N-linked glycans regardless of their matu-
ration stage, revealed the gM protein backbone of about 34
kDa (lanes 2 and 5). Upon digestion with endoglycosidase H
(EndoH), the 36-kDa species was lost, thus identifying this
band as the immature form of gM (compare lanes 3 and 4 as
well as lanes 6 and 7).
When gM was expressed in the absence of UL49.5, only the
36-kDa immature form could be detected (Fig. 1A, lane 9).
This product was EndoH sensitive (lane 10), indicating that
UL49.5 is required for maturation of gM. Coimmunoprecipi-
tation experiments performed on MJS UL49.5/gM cells indi-
cated that UL49.5 can indeed form a complex with gM outside
the context of a viral infection (Fig. 1B). Staining of a gM
immunoprecipitate with anti-UL49.5 antibodies revealed the
coprecipitation of UL49.5 (Fig. 1B, lane 2, lower panel). Con-
versely, anti-UL49.5 antibodies coprecipitated gM (Fig. 1B,
lane 3, upper panel).
The transmembrane region of UL49.5 is important for func-
tional processing of gM. To investigate which domain(s) of
UL49.5 contributes to the processing of gM, its maturation was
analyzed in MJS cells transduced with a gM-expressing retro-
virus in combination with a second retroviral vector expressing
one of the truncated forms of UL49.5 (Fig. 1C). Deletion of
the cytoplasmic tail of UL49.5 did not influence processing of
gM (lane 2). Coexpression of gM with a form of UL49.5 lack-
ing the cytoplasmic tail and the transmembrane domain did
not result in maturation of gM (Fig. 1C, lane 3). This result
indicates that the transmembrane domain of UL49.5, in com-
bination with its ER-lumenal/extracellular domain, is required
for proper maturation of gM.
Coexpression of UL49.5 and gM results in the redistribu-
tion of both proteins to the TGN. To study the influence of
coexpression of gM and UL49.5 on their subcellular distribu-
tion, immunofluorescence-confocal laser scanning microscopy
was performed on MJS, MJS gM, MJS UL49.5, and MJS
UL49.5/gM cells. Colocalization with the trans-Golgi network
(TGN) marker Golgin 97 was also investigated. The expression
of the individual gM and UL49.5 proteins in the absence of
their counterparts resulted in a dispersed granular staining
pattern, reminiscent of intracellular membranes. No colocal-
ization with the TGN could be observed (Fig. 2D to F and M
to O). The localization of UL49.5 was in accordance with
previous observations in MJS TAP1-GFP UL49.5-expressing
cells (18). UL49.5-gM coexpression resulted in a redistribution
of both proteins to the TGN, where they colocalized with
Golgin 97 (Fig. 2G to I and P to R). Taken together, these data
show that coexpression of UL49.5 and gM facilitates their
transport to distal Golgi compartments and guides the UL49.5
protein away from the endoplasmic reticulum, the site of TAP
inhibition.
gM influences the UL49.5-mediated inhibition of TAP. To
study the consequences of the complex formation of UL49.5
and gM, three aspects of the UL49.5 interference with the
MHC class I antigen presentation pathway were analyzed.
First, peptide transport activity of TAP was measured in cells
expressing UL49.5 in the absence or presence of gM. As re-
ported before (18), the expression of UL49.5 alone results in
an almost complete block of peptide translocation by TAP
(Fig. 3A). Coexpression of gM with UL49.5 restored TAP
activity to 85% of normal transport in control cells. Second, it
was analyzed whether coexpression of gM had an effect on
TAP degradation by UL49.5. To this end, steady-state levels of
TAP1 and TAP2 proteins were compared in MJS UL49.5, MJS
gM, MJS UL49.5/gM, and control MJS cells. Immunoblotting
analysis revealed that gM counteracted the UL49.5-mediated
degradation of TAP (Fig. 3B, compare lanes 2 and 4). The
levels of both TAP proteins in UL49.5/gM cells appeared to be
indistinguishable from those in the control cells (compare
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lanes 1 and 4). The gM protein alone had no effect on TAP
stability (lane 3).
Third, the downregulation of surface MHC class I expres-
sion by UL49.5 was analyzed in the presence of gM. This
analysis showed that the majority of the UL49.5/gM cells re-
tained an unaffected cell surface level of MHC class I mole-
cules (Fig. 3C, compare boldface histograms 2 and 3). The
observed differences between the UL49.5-expressing and
UL49.5-gM-coexpressing cells were not caused by reduced
UL49.5 expression, as comparable levels of UL49.5 could be
detected in both cell lines (Fig. 3D). These data show that gM
can counteract the inhibitory effect of UL49.5 on the function
and stability of the TAP transporter and, consequently, can
restore cell surface expression of MHC class I molecules.
Kinetics of expression of UL49.5 and gM differ during
BHV-1 infection. To further study the influence of gM on
UL49.5, the kinetics of UL49.5 and gM synthesis was analyzed
during BHV-1 infection. MJS or MDBK cells were infected
with BHV-1 at a multiplicity of infection (MOI) of 10, and then
the cells were collected at 0, 3, 5, 8, and 12 h postinfection (hpi)
and metabolically labeled with [35S]cysteine/methionine mix
for 35 min. UL49.5 and gM were immunoprecipitated from the
cell lysates. UL49.5 could be detected in MJS as early as 3 hpi
(Fig. 4A, left panel) and continued to be detectable at all later
time points postinfection. Coprecipitation of gM with UL49.5
was observed at 8 and 12 hpi (Fig. 4A, left panel). To assess the
sensitivity of the UL49.5 and gM expression to phosphonoace-
tic acid (PAA), a DNA replication inhibitor that allows dis-
crimination between the intermediate-early/early and late pro-
teins (28), the cells were infected in the absence or presence of
PAA. UL49.5 synthesis was not affected by PAA treatment. As
a control, the early glycoprotein B (gB) and the late BHV-1
virion host shutoff (vhs) protein, a homolog of the HSV-1
UL41-encoded protein (36), were precipitated from the same
lysates. PAA treatment only marginally affected the expression
of gB and significantly inhibited the synthesis of the vhs protein
(Fig. 4B).
Glycoprotein M species (45 kDa, 36 kDa, and 34 kDa)
were detected in MJS cells late in infection (starting be-
tween 5 and 8 hpi; Fig. 4A, right panel), confirming previ-
FIG. 1. UL49.5 is required for gM maturation. (A) Cell lysates of control MJS (c), BHV-1-infected MJS, and MJS stably expressing gM or
UL49.5/gM were treated with endoglycosidase H (EndoH) () or left untreated (). The EndoH-resistant forms (gM EndoH R), the EndoH-
sensitive form (gM EndoH S), and the peptide:N-glycosidase F (PNGaseF)-treated, deglycosylated form of gM (gM-CHO) were detected by
immunoblotting with gM-specific antibodies. (B) UL49.5 and gM form a complex in MJS UL49.5/gM cells. UL49.5 or gM was immunoprecipitated
(IP) with specific rabbit antibodies from control (c) or UL49.5/gM-coexpressing cells. Immunoprecipitates were separated by SDS-PAGE and
stained by immunoblotting (WB) with mouse antibodies against either gM (upper panel) or UL49.5. (C) The transmembrane region of UL49.5
is important for functional processing of gM. The mature gM (solid circle) could be detected by immunoblotting either in full-length UL49.5/
gM-coexpressing or tailless UL49.5/gM-coexpressing MJS (MJS UL49.5 tail/gM). Coexpression of UL49.5 lacking both its tail and transmem-
brane region in MJS UL49.5 tail TM/gM cells resulted in impaired maturation of high-mannose gM (open circle), comparable to MJS
gM-expressing cells. The 34-kDa gM precursor is indicated with a dashed circle. c, control MJS; *, immunoglobulin heavy chain. Size markers are
in kilodaltons.
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ously published results (39). The 9-kDa protein coprecipi-
tating with gM presumably represents UL49.5 (Fig. 4A,
right panel). The synthesis of gM was blocked by PAA,
which is typical for late proteins (28).
In the bovine MDBK cells, the interaction of UL49.5 and
gM was observed as well (Fig. 4C). The early glycoprotein B
and the late proteins gC and vhs were taken along as controls
for PAA-mediated inhibition of late gene expression (Fig. 4D).
FIG. 2. Subcellular redistribution of UL49.5/gM analyzed by confocal laser scanning microscopy. gM was detected with gM-specific rabbit antibodies
in MJS (A and C), MJS gM (D and F), or MJS UL49.5/gM (G and I). UL49.5 was detected with UL49.5-specific rabbit antibodies in MJS (J and L),
MJS UL49.5 (M and O), or MJS UL49.5/gM (P and R). The trans-Golgi compartment was stained with MAb anti-Golgin 97 (B, E, H, K, N, and Q).
The anti-gM and anti-UL49.5 rabbit antibodies were visualized with Alexa 594-conjugated goat anti-rabbit IgG. Golgin 97 was visualized with Alexa
633-conjugated goat anti-mouse IgG, and the signal was electronically converted into green. In the overlays, colocalization is shown in yellow.
5826 LIPIN´SKA ET AL. J. VIROL.
 at LAN
D
BO
UW
UNIVERSITEIT on February 12, 2008 
jvi.asm.org
D
ow
nloaded from
 
Taken together, these data show that UL49.5 is produced as an
early and late protein, whereas gM occurs as a late glycopro-
tein in BHV-1-infected cells. Both proteins were found to
interact upon expression of gM at later stages of infection.
BHV-1 inhibits TAP-dependent peptide transport, also at
late stages of infection. Given the possibility that gM can
counteract the inhibition of TAP by UL49.5, the observed
interference with TAP function at early stages of infection with
BHV-1 may be understandable on the basis of the late expres-
sion of gM. Knowing that gM synthesis occurs at later stages
and results in UL49.5/gM complexes, TAP inhibition was stud-
ied in MJS cells infected with BHV-1 at 12 hpi. To exclude a
potential virion host shutoff (vhs) effect on the synthesis of
TAP or other components of the peptide-loading complex,
peptide transport by TAP was evaluated in cells infected with
either wild-type BHV-1 or a BHV-1 vhs deletion mutant. Un-
der both conditions, a strong inhibition of TAP transport was
observed (Fig. 5A), comparable to the inhibition observed
during earlier times of infection (20). The UL49.5 protein and
gM, detected in the tested cells by immunoblotting, are shown
in Fig. 5B. As the vast majority of BHV-1-infected cells re-
mained 7-AAD negative at 12 hpi (Fig. 5C), it was unlikely that
the inhibition of TAP function was caused by reduced viability
of the cells. These results indicate that TAP transport is effi-
ciently blocked also at a late stage of infection, when both
UL49.5 and gM are present in the infected cells. Thus, it was
concluded that the expression of gM at later stages of BHV-1
infection does not prevent inactivation of TAP.
UL49.5 is produced in excessive amounts in BHV-1-infected
cells, and only a proportion of it is incorporated into
UL49.5-gM complexes. To investigate why gM does not coun-
teract the inhibitory effect of UL49.5 on TAP in BHV-1-in-
fected cells, the UL49.5/gM complex formation was studied in
more detail during infection. The interaction between UL49.5
and gM is stabilized by a disulfide bridge between gM and the
single cysteine within the ER-luminal/extracellular domain of
UL49.5. Therefore, complex formation was evaluated under
nonreducing conditions. MJS or MDBK cells were infected
with BHV-1 at an MOI of 10, collected at 0, 2, 4, 6, and 10 hpi,
and metabolically labeled with [35S]cysteine/methionine for 35
min. UL49.5 was immunoprecipitated from digitonin lysates,
and the resulting immune complexes were separated using
nonreducing SDS-PAGE. At early stages of infection, UL49.5
was detected as a monomer and a dimer, migrating in the
FIG. 3. gM interferes with UL49.5-mediated inactivation of TAP. (A) UL49.5 inhibition of TAP-dependent peptide transport is not observed
in MJS UL49.5/gM cells. The translocation of fluorescent peptides in MJS UL49.5 or MJS UL49.5/gM cells is represented as a percentage of the
translocation in control (c) MJS cells. FL, fluorescein. (B) UL49.5/gM coexpression results in the stabilization of TAP1 and TAP2 protein levels.
Steady-state levels of TAP1, TAP2, and beta-actin were evaluated by immunoblotting in control (c) MJS, MJS UL49.5, MJS gM, or MJS
UL49.5/gM cells using specific antibodies; *, unidentified background protein. (C) Downregulation of MHC class I surface expression by UL49.5
in the absence (upper panel, boldface line, no. 2) or in the presence of gM (lower panel, boldface line, no. 3). Thin line, MHC I in MJS cells (no.
1); dashed line, goat anti-mouse phycoerythrin control (c). (D) Immunoblot analysis of UL49.5 expression in MJS cells expressing UL49.5 or
coexpressing UL49.5 and gM. Uninfected and BHV-1-infected MJS cells were included as controls.
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nonreducing gels at 9 and 15 kDa, respectively. Glycoprotein
M was not present in these complexes, which is in agreement
with the synthesis of UL49.5 prior to the production of gM in
BHV-1-infected cells. The 15-kDa product was sensitive to
reducing agents, indicating that it corresponds to dimers of
UL49.5 (39). The UL49.5 monomers and dimers persist
throughout infection, despite the synthesis of gM at later time
points. Based on the electrophoretic mobility and endoglyco-
sidase H digests (data not shown), it was possible to define the
48-kDa protein band as the mature gM-UL49.5 heterodimer,
the 43-kDa band as the high-mannose gM-UL49.5 het-
erodimer, and the 39-kDa band as the precursor gM-UL49.5
heterodimer (Fig. 6A).
As an alternative approach to detect free UL49.5 protein in
gM-expressing cells, UL49.5/gM complexes were first depleted
by precipitation with excess of anti-gM antibodies in three
consecutive rounds, followed by immunoprecipitation of the
lysates with anti-UL49.5 antibodies. Only minute amounts
of gM could be isolated from the gM-depleted cell lysates
(Fig. 6B, lane 4). In contrast, UL49.5 could be precipitated
in significant quantities from the depleted lysates (Fig. 6B,
lane 5).
Also in BHV-1-infected MDBK cells, monomeric and di-
meric UL49.5 was seen simultaneously with UL49.5/gM com-
plexes when the experiment was performed under nonreducing
conditions (Fig. 6C, lanes 10 and 11). The amounts of
UL49.5/gM complexes isolated with either anti-gM or anti-
UL49.5 antibodies were comparable, but the UL49.5-specific
serum additionally yielded considerable quantities of mono-
meric and dimeric UL49.5. These results illustrate that the
complex of gM and UL49.5 did not dissociate in the course of
the experiment. If that had been the case, lower-molecular-
mass forms of gM would have been observed in the gM im-
munoprecipitates in addition to the UL49.5/gM complexes.
This was not the case. This experiment indicates that signifi-
cant quantities of free UL49.5 are present in infected cells,
despite the expression of gM.
Immunofluorescence experiments were performed in BHV-
1-infected cells to investigate whether the non-gM-associated
UL49.5 can be detected in the ER. UL49.5 staining was ob-
served in the ER and beyond (Fig. 7M to R), possibly in the
TGN and transport vesicles. Glycoprotein M was detectable in
the Golgi and post-Golgi compartments (Fig. 7D to I). The
fact that UL49.5 could be detected in the ER when gM was
FIG. 4. UL49.5 and gM are expressed with different kinetics during BHV-1 infection. MJS cells were infected with BHV-1 in the absence or
presence of phosphonoacetic acid (PAA and PAA, respectively), collected at the indicated time points postinfection (hpi), and metabolically
labeled for 35 min. (A) UL49.5 (left panel) or gM (right panel) was immunoprecipitated from cell lysates with anti-UL49.5 and anti-gM antibodies,
respectively. The fully glycosylated gM (solid circle), the high-mannose gM (open circle), and the gM precursor (dashed circle) are indicated.
(B) The early glycoprotein B or the late virion host shutoff (vhs) protein were immunoprecipitated from the cell lysates as controls. (C) The
experiment is the same as that described for panel A, performed in MDBK cells. (D) The early gB, the late gC, and the late vhs protein
immunoprecipitated from the MDBK cell lysates. Size markers are in kilodaltons.
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expressed (10 and 14 hpi) supports the biochemical data indi-
cating that UL49.5 remains capable of blocking TAP in the ER
of BHV-1-infected cells despite the expression of gM.
Taken together, these results indicate that considerable
amounts of free monomeric and dimeric UL49.5 protein are
present in BHV-1-infected cells; only a proportion of the
UL49.5 protein is engaged in UL49.5/gM complex formation.
DISCUSSION
The study reported here was motivated by the recent iden-
tification of the BHV-1 UL49.5 protein as an inhibitor of the
TAP transporter (18), in addition to its known interaction with
gM, with which it forms a complex in infected cells (39). The
heterodimer formation with another viral component makes
UL49.5 unique amid presently known herpesvirus-encoded
TAP inhibitors, including the herpes simplex virus-encoded
ICP47 (7, 13), the human cytomegalovirus-encoded US6 (1, 12,
24), and murine gammaherpervirus 68-encoded mK3 (3, 4, 29).
The latter inhibitors were described to occur in monomeric
forms (1, 2, 22, 38). The interaction of gM with UL49.5 sug-
gested that the former might act as a modulator of TAP inhi-
bition by UL49.5. Hence, the UL49.5-mediated inactivation of
TAP was studied in cells coexpressing gM. UL49.5 and gM
appeared to form a complex outside the context of BHV-1
infection, indicating that no other viral (glyco)proteins are
required for this interaction. The biochemical data presented
in this study clearly indicate that UL49.5 is required for mat-
uration of gM. Immunofluorescence-confocal laser scanning
microscopy data support this conclusion. Whereas the individ-
ually expressed UL49.5 and gM proteins are retained in the
ER, simultaneous expression of both proteins results in their
transport to the trans-Golgi compartments. At present, it is
unclear how UL49.5 influences the maturation of gM and
promotes its egress from the ER. For the interaction of UL49.5
with the TAP complex, the cytoplasmic tail of UL49.5 is not
needed (18). The extracellular domain and the transmembrane
region of UL49.5 are sufficient to induce structural changes in
the TAP complex that block its function. By analogy, these
regions of UL49.5 are sufficient to mediate its interaction with
gM. This arrangement may influence the conformation of gM
and facilitate its export from the ER. Although not needed for
the interaction with the TAP complex or for inhibition of
peptide transport by TAP, the cytoplasmic tail of UL49.5 plays
an essential role in the degradation of the TAP proteins by the
proteasome (18).
Coexpression of UL49.5 and gM prevents the inhibition of
TAP by UL49.5. As the UL49.5/gM complex formation results
in its transport to the trans-Golgi compartment, this diminishes
the pool of UL49.5 protein available for TAP inhibition in the
ER. Whether at any stage during this competition the gM
protein forms a part of the UL49.5-TAP complex is unclear.
Attempts to show the presence of gM in immunoprecipitates
of the TAP complex in BHV-1-infected cells have been unsuc-
cessful (data not shown).
The studies performed in transduced cells were comple-
mented with experiments in BHV-1-infected cells, in which the
biosynthesis of UL49.5 and gM, as well as their interaction, was
studied in a time-dependent fashion. The results show for the
first time that UL49.5 of BHV-1 is expressed in the presence of
PAA as an early protein and continues to be expressed as a late
protein. In agreement with earlier observations (39), BHV-1
gM is a late protein. This creates a time window for UL49.5 to
act on TAP without gM interference. Furthermore, our study
indicates that when gM is expressed, only a fraction of UL49.5
is engaged in a complex with gM. Consequently, also at later
stages of infection, sufficient gM-free UL49.5 protein is avail-
FIG. 5. BHV-1 inhibits ATP-dependent peptide transport by TAP
at late stages of infection. MJS cells were infected with wild-type (wt)
BHV-1 or a virion host shutoff deletion (vhs) mutant for 12 h.
(A) TAP-dependent peptide transport was assessed in the presence or
absence of ATP using a fluorescein (FL)-tagged peptide. Uninfected
MJS cells were used as a control. FL-peptide translocation in infected
cells is represented as a percentage of the translocation in uninfected
cells (set as 100%). (B) gM and UL49.5 detected in the BHV-1-
infected cells used in the TAP transport assays shown in panel A. The
cell lysates were separated by SDS-PAGE and analyzed by immuno-
blotting using antibodies against gM (upper panel) or UL49.5 (lower
panel). Size markers are in kilodaltons. (C) The viability of the BHV-
1-infected cells was evaluated at 12 hpi by 7-AAD staining and flow
cytometry. FSC, forward scatter.
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able to inhibit TAP effectively. This is in agreement with the
observed TAP inhibition at 12 hpi.
The conservation of coding sequences for UL49.5/gN and
gM homologs in the genomes of Alpha-, Beta-, and Gamma-
herpesvirinae for more than 200 million years suggests that
these proteins have an important function in the life cycle of
herpesviruses (6). All presently studied gN and gM homologs
form a heterodimeric complex in which at least one partner is
glycosylated (8, 15, 21, 23, 30, 34, 38). It is believed that this
complex represents a functional unity and is implicated in
virion maturation (23, 31, 35) and the control of membrane
fusion (16, 17, 18). The inhibition of TAP by UL49.5 homologs
seems to be a function that evolved more recently, as it could
be demonstrated only for a number of varicelloviruses (18).
The UL49.5 proteins of herpes simplex virus types 1 and 2 do
not block TAP. The latter function is performed by their re-
spective ICP47 proteins (16–21). Also, beta- and gammaher-
pesviruses have developed other mechanisms to block TAP
and evade cytotoxic T-cell recognition (27, 33).
Despite the inhibition of TAP and the downregulation of
MHC class I cell surface expression, BHV-1 evokes a T-cell
response in its host, implying that at some stage of infection,
BHV-1 peptides are presented to the immune system. This
has also been observed for other herpesviruses. Presumably,
FIG. 6. UL49.5 is present in excess during BHV-1 infection. (A) BHV-1-infected MJS cells were collected at the indicated time points
postinfection and metabolically labeled for 35 min. Cell lysates were subjected to immunoprecipitation with anti-UL49.5 antibodies and analyzed
using nonreducing SDS-PAGE. Monomeric UL49.5 (solid arrow), UL49.5 dimers (double solid arrow), fully glycosylated gM-UL49.5 heterodimers
(solid circle, solid arrow), high-mannose gM-UL49.5 heterodimers (open circle, solid arrow), and precursor gM-UL49.5 heterodimers (dashed
circle, solid arrow) are indicated. (B) Mock-infected control cells (c) or BHV-1-infected cells were collected at 8.5 hpi and metabolically labeled
for 30 min. Cell lysates were subjected to three sequential rounds of immunoprecipitation (IP) with anti-gM antibodies. After the third IP with
gM, the lysate was subjected to a fourth, final IP with anti-UL49.5. (C) BHV-1-infected MDBK cells were collected at the indicated time points
postinfection and metabolically labeled for 35 min. Cell lysates were subjected to immunoprecipitation with anti-gM (left panel) or anti-UL49.5
(right panel) antibodies and analyzed using nonreducing SDS-PAGE. Monomeric UL49.5, UL49.5 dimers, fully glycosylated gM-UL49.5 het-
erodimers, high-mannose gM-UL49.5 heterodimers, and precursor gM-UL49.5 heterodimers are indicated as for panel A. Size markers are in
kilodaltons.
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the immune evasion proteins delay recognition of the in-
fected cells, thus creating a time window for undetected
virus replication. In summary, under experimental condi-
tions, BHV-1 gM can block the inhibition of the TAP trans-
porter by UL49.5. In BHV-1-infected cells, however, this
effect is not observed due to a temporal difference in UL49.5
and gM expression, combined with a relative overexpression
of UL49.5.
FIG. 7. Subcellular redistribution of UL49.5 and gM in BHV-1-infected MDBK cells, analyzed by confocal laser scanning microscopy. MDBK
cells were infected with BHV-1 at an MOI of 1. gM was detected in infected cells with gM-specific rabbit antibodies at the indicated times
postinfection (B, C, E, F, H, and I). UL49.5 was detected with UL49.5-specific rabbit antibodies (K, L, N, O, Q, and R). The ER/cis-Golgi was
stained with concanavalin A-Alexa 488 (A, C, D, F, G, I, J, L, M, O, P, and R). The anti-gM and anti-UL49.5 rabbit antibodies were visualized
with Alexa 594-conjugated goat anti-rabbit IgG. In the overlays, colocalization is shown in yellow.
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